SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biomatrix (BXM) Looking Great
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: dalroi who wrote (557)3/8/2000 7:13:00 AM
From: Greg Jung  Read Replies (1) of 569
 
Maybe they've got enough insiders and other holders
on board. All they need is to get some analysts to
say a few words and the point will become moot. Of
course, there are no guarantees but this looks close.


BioMatrix shareholders will have the option of receiving $37 in cash or one share of Genzyme Biosurgery for
each BioMatrix share.

The cash portion of the transaction will be about $245 million, the companies said.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News